Red Leaf Medical is pleased to announce the Canadian launch of PROfortil™, a clinically proven treatment for male fertility disorders that contains a patented composition of micronutrients. According to the Government of Canada Report on Fertility, approximately 16%, or one in six couples, experience infertility…
Red Leaf Medical has signed an exclusive Canadian distribution agreement with Inmunotek, a leading pharmaceutical company based in Spain, to commercialize UROMUNE®, a novel sublingual vaccine for the treatment of recurrent urinary tract infection.
Canadian Business and PROFIT unveiled its list of the fastest growing companies and ranked Red Leaf Medical on the 29th annual PROFIT 500, the definitive ranking of Canada’s Fastest-Growing Companies.
Red Leaf Medical Inc. has signed an exclusive agreement with Lenus Pharma, a leading Austrian pharmaceutical company specializing in fertility, to commercialize PROfortil™ in Canada. PROfortil™ is a clinically proven treatment that contains a patented composition of micronutrients that aid in fertility.
Canadian Business and PROFIT today listed Red Leaf Medical Inc. on the 28th annual PROFIT 500, the definitive ranking of Canada’s Fastest-Growing Companies.
Biotechnology Focus, a leading Life Sciences Publication in Canada, has profiled Red Leaf Medical as an innovative company building a strong reputation with great products and a passionate focus on meeting patients’ needs.
Canadian Business and PROFIT today ranked Red Leaf Medical No. 38 on the 27th annual PROFIT 500, the definitive ranking of Canada’s Fastest-Growing Companies.